Licensing agreement for CIN-107License Agreement • September 11th, 2024
Contract Type FiledSeptember 11th, 2024CinCor Pharma has signed an agreement with Roche to acquire exclusive global rights to a novel aldosterone synthase inhibitor (ASI) compound, CIN-107.